Home / Market News / $EYPT
benzinga Corporate Catalyst Impact 95/100 ● negative

EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus

Oct 19, 2026, 5:16 PM UTC · Primary ticker $EYPT

EyePoint Inc. is undergoing a significant restructuring, cutting over half its workforce and discontinuing its wet age-related macular degeneration (AMD) clinical trials due to disappointing Phase 3 results. This strategic pivot focuses all resources on its diabetic macular edema (DME) program, leading to a substantial drop in stock price.

EyePoint Inc. announced a major strategic shift following the failure of its LUCIA Phase 3 trial for wet AMD to meet its primary endpoint. This led to a drastic 53% workforce reduction and the complete cessation of its wet AMD program, aiming to conserve capital and redirect resources entirely to its DME treatment, DURAVYU. The immediate impact is severely negative for EYPT shareholders, as evidenced by the 85.46% stock price drop. While the company aims for long-term viability by focusing on a more promising pipeline, the short-term outlook is highly volatile and negative due to the significant setback and associated costs of restructuring.

$EYPT negative Failed Phase 3 trial, massive layoffs, strategic pivot
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.